Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5727MR)

This product GTTS-WQ5727MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5727MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14528MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ7949MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ6796MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ6905MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ8117MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ7163MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ3384MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ13689MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW